BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

669 related articles for article (PubMed ID: 12007942)

  • 1. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas.
    Levin VA; Yung WK; Bruner J; Kyritsis A; Leeds N; Gleason MJ; Hess KR; Meyers CA; Ictech SA; Chang E; Maor MH
    Int J Radiat Oncol Biol Phys; 2002 May; 53(1):58-66. PubMed ID: 12007942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme.
    Levin VA; Maor MH; Thall PF; Yung WK; Bruner J; Sawaya R; Kyritsis AP; Leeds N; Woo S; Rodriguez L
    Int J Radiat Oncol Biol Phys; 1995 Sep; 33(2):357-64. PubMed ID: 7673023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.
    Buckner JC; Shaw EG; Pugh SL; Chakravarti A; Gilbert MR; Barger GR; Coons S; Ricci P; Bullard D; Brown PD; Stelzer K; Brachman D; Suh JH; Schultz CJ; Bahary JP; Fisher BJ; Kim H; Murtha AD; Bell EH; Won M; Mehta MP; Curran WJ
    N Engl J Med; 2016 Apr; 374(14):1344-55. PubMed ID: 27050206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas.
    Levin VA; Prados MR; Wara WM; Davis RL; Gutin PH; Phillips TL; Lamborn K; Wilson CB
    Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):75-83. PubMed ID: 7721642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PC or PCV, That Is the Question: Primary Anaplastic Oligodendroglial Tumors Treated with Procarbazine and CCNU With and Without Vincristine.
    Webre C; Shonka N; Smith L; Liu D; De Groot J
    Anticancer Res; 2015 Oct; 35(10):5467-72. PubMed ID: 26408710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined treatment modality for anaplastic oligodendroglioma: a phase II study.
    Jeremic B; Shibamoto Y; Gruijicic D; Milicic B; Stojanovic M; Nikolic N; Dagovic A; Aleksandrovic J
    J Neurooncol; 1999 Jun; 43(2):179-85. PubMed ID: 10533731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study.
    Soffietti R; Nobile M; Rudà R; Borgognone M; Costanza A; Laguzzi E; Mutani R
    Cancer; 2004 Feb; 100(4):807-13. PubMed ID: 14770438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study.
    Brandes AA; Tosoni A; Vastola F; Pasetto LM; Coria B; Danieli D; Iuzzolino P; Gardiman M; Talacchi A; Ermani M
    Cancer; 2004 Nov; 101(9):2079-85. PubMed ID: 15372474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children.
    Levin VA; Lamborn K; Wara W; Davis R; Edwards M; Rabbitt J; Malec M; Prados MD
    Neuro Oncol; 2000 Jan; 2(1):22-8. PubMed ID: 11302250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas.
    Levin VA; Hess KR; Choucair A; Flynn PJ; Jaeckle KA; Kyritsis AP; Yung WK; Prados MD; Bruner JM; Ictech S; Gleason MJ; Kim HW
    Clin Cancer Res; 2003 Mar; 9(3):981-90. PubMed ID: 12631596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951.
    Gorlia T; Delattre JY; Brandes AA; Kros JM; Taphoorn MJ; Kouwenhoven MC; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; van den Bent MJ
    Eur J Cancer; 2013 Nov; 49(16):3477-85. PubMed ID: 23896377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.
    Buckner JC; Gesme D; O'Fallon JR; Hammack JE; Stafford S; Brown PD; Hawkins R; Scheithauer BW; Erickson BJ; Levitt R; Shaw EG; Jenkins R
    J Clin Oncol; 2003 Jan; 21(2):251-5. PubMed ID: 12525516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemo-radiotherapy for malignant brain tumors].
    Kochi M; Ushio Y
    Gan To Kagaku Ryoho; 2002 May; 29(5):669-76. PubMed ID: 12040669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy.
    Glass J; Hochberg FH; Gruber ML; Louis DN; Smith D; Rattner B
    J Neurosurg; 1992 May; 76(5):741-5. PubMed ID: 1564535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial chemotherapy in gliomatosis cerebri.
    Sanson M; Cartalat-Carel S; Taillibert S; Napolitano M; Djafari L; Cougnard J; Gervais H; Laigle F; Carpentier A; Mokhtari K; Taillandier L; Chinot O; Duffau H; Honnorat J; Hoang-Xuan K; Delattre JY;
    Neurology; 2004 Jul; 63(2):270-5. PubMed ID: 15277619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors.
    Streffer J; Schabet M; Bamberg M; Grote EH; Meyermann R; Voigt K; Dichgans J; Weller M
    J Neurol; 2000 Apr; 247(4):297-302. PubMed ID: 10836623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy.
    Prados MD; Scott C; Curran WJ; Nelson DF; Leibel S; Kramer S
    J Clin Oncol; 1999 Nov; 17(11):3389-95. PubMed ID: 10550132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
    van den Bent MJ; Dubbink HJ; Sanson M; van der Lee-Haarloo CR; Hegi M; Jeuken JW; Ibdaih A; Brandes AA; Taphoorn MJ; Frenay M; Lacombe D; Gorlia T; Dinjens WN; Kros JM
    J Clin Oncol; 2009 Dec; 27(35):5881-6. PubMed ID: 19901104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined treatment modality for anaplastic oligodendroglioma and oligoastrocytoma: a 10-year update of a phase II study.
    Jeremic B; Milicic B; Grujicic D; Samardzic M; Antunovic V; Dagovic A; Aleksandrovic J
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):509-14. PubMed ID: 15145170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.
    van den Bent MJ; Carpentier AF; Brandes AA; Sanson M; Taphoorn MJ; Bernsen HJ; Frenay M; Tijssen CC; Grisold W; Sipos L; Haaxma-Reiche H; Kros JM; van Kouwenhoven MC; Vecht CJ; Allgeier A; Lacombe D; Gorlia T
    J Clin Oncol; 2006 Jun; 24(18):2715-22. PubMed ID: 16782911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.